The new rules are intended to bridge the gap between the DEA’s current PHE waivers and a post-PHE telehealth environment, according to a Feb. 24 release from the DEA.
Four things to know:
- The new rules would provide safeguards for telemedicine consultations conducted by a medical practitioner that has never met with a patient in-person and controlled substance prescribing via telemedicine.
- The new rules would allow practitioners to prescribe a 30-day supply of Schedule III-V non-narcotic controlled medications via telemedicine.
- The new rules would also allow practitioners to prescribe a 30-day supply of buprenorphine for the treatment of opioid use disorder via telemedicine.
- These new rules would allow clinicians to prescribe these substances without an in-person evaluation or referral from a medical practitioner, as long as the prescription is consistent with federal and state laws.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
